Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.05), $0.09 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $50.03 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart shares fall despite earnings beat
• Walmart (WMT) PT Lowered to $130 at Goldman Sachs